Brain Tumor Research and Treatment | Ivy Brain Tumor Center

3 Things You Need to Know

Doctor speaking with his patient in the office

Standard of care

Isn't working

The current standard of care for patients with aggressive brain tumors like glioblastoma is not curative and most patients experience tumor progression after treatment. Learn More

Researcher looking in microscope

You need

Individualized treatment

Unlike other cancers such as breast or lung, brain tumors are extremely genetically heterogeneous and require a treatment regimen that is tailored to your individual tumor. Learn More

Family photo of a husband, wife, and their two young boys

Time

Is of the essence

Conventional clinical trials can take months to inform patients if a therapy is working. This is time you simply do not have to invest. Learn More

Phase 0 Trials

Ivy Phase 0 clinical trials allow patients to receive individualized treatment in a fraction of the time and costs associated with traditional drug research and development.

Benefits of an Ivy Phase 0 Trial

Saves Valuable Time

Drug effects on a patient’s tumor are directly measured within 10 days of surgery. If an experimental regimen is ineffective, the patient can transition to another type of therapy without losing time or options.

Personalizes Treatment

Genetic testing with unprecedented depth allows us to match tumors to new combination drug regimens. Due to the speed in which our trials open and close, we are able to test more new therapies than any other clinical trials program.

Tests New Drugs

Every Ivy Center drug combination tests new mechanisms never before trialed in brain tumor patients. As a nonprofit organization, there is no conflict of interest or hidden agenda in selecting which drugs to include in our program.

Dr. Patricia Tagle-Levy

PATIENT EXPERIENCE

Patricia: Clinical Trial Patient

When Patricia’s glioblastoma came back after her first surgery, she and her husband both knew it was time to start looking at alternative treatment options. After extensive research, they discovered the hope they were looking for was actually right in their backyard at the Ivy Center in Phoenix.

Read Full Story

View Open Trials

Gliomas

Common subtypes include astrocytoma, oligodendroglioma, glioblastoma, and gliosarcoma

Brain Metastases

Also known as ‘secondary’ brain tumors; originate from cancer in another part of the body

Meningiomas

Primary brain tumors derived from the lining of the brain, known as the meninges

Ependymomas

Arises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord

Craniopharyngiomas

Arises from small nests of cells near the pituitary stalk at the base of the skull, near the pituitary gland, third ventricle, and optic nerve

Pineal-Region Tumors

Occurs in the pineal region of the brain that may or may not involve the pineal gland

COMMUNITY OF CAREGIVERS

Recovering glioblastoma patient with his family

Glioblastoma Patient Defying the Odds Three Years After Diagnosis

October 6, 2022
Posted in Patient Stories

Brain cancer survivor Dalton Riddle is defying the odds. He’s about to celebrate living three years with glioblastoma. For most, the average life expectancy after diagnosis is 12-15 months. Read his survivorship story and how he supports others facing a similar diagnosis.

Postdoctoral Fellow working Ivy Lab

Ivy Brain Tumor Center Announces Initial Results of Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma at the European Society for Medical Oncology (ESMO) 2022 Congress

September 10, 2022

Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.

Pharmacokinetics and Pharmacodynamics lab group photo

Ivy Brain Tumor Center’s Core Laboratories Awarded Accreditation by the College of American Pathologists

December 21, 2021

The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).

Patient with a brain tumor, receiving liquid CSF biopsy

Ivy Brain Tumor Center Implements New Liquid Biopsy Program to Provide Glioblastoma Patients More Personalized Care

September 7, 2022

The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.

Michelle with her mom

Parents With Glioblastoma: A Daughter Shares Story of Mother’s Diagnosis

July 18, 2022
Posted in Patient Stories

Finding out a parent has been diagnosed with glioblastoma can be overwhelming. Finding answers and support becomes top priority. Read about a daughter, her mom and their brain cancer story.

Digital tablet being held in front of MRI machine

Robust 2022 Glioblastoma Clinical Trials Program Offers Brain Cancer Patients New Treatment Options

February 15, 2022
Posted in Clinical Trials

Our team of brain tumor experts have compiled everything you need to know about our clinical trials, including the rationale behind the novel drugs and devices we’re investigating as well as some of the initial results we’re seeing in brain cancer patients.

Brain tumor research HQ to be built on St. Joseph’s Phoenix campus

July 29, 2021
Source: Phoenix Business Journal

The Ivy Brain Tumor Center at Barrow Neurological Institute plans to build its 75,000-square-foot global headquarters on the campus of St. Joseph’s Hospital and Medical Center in Phoenix.

Am I Eligible?

Submit a Trial Screening Request today and an Ivy Navigator will contact you within 48 hours to complete the initial patient assessment.

Determine your Eligibility